DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR LEUSTATIN
» See Plans and Pricing
All Clinical Trials for Leustatin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00667329 | Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab | Active, not recruiting | M.D. Anderson Cancer Center | N/A | 1999-07-01 | The goal of this clinical research study is to see how well the drugs 2CdA, cyclophosphamide, and rituximab (rituxan) shrink a lymphoma called Waldenstrom's macroglobulinemia. After these drugs are given for 2 courses, a second goal is to see how long a remission lasts. A third goal is to see how often repeat remissions can be achieved when the lymphoma returns later and the same drugs are restarted. |
| NCT01513603 | Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia | Unknown status | New York Medical College | Phase 2 | 2012-01-01 | CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the efficacy of the regimen in patients with relapsed ALL. |
| NCT03012672 | Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm | Not yet recruiting | National Cancer Institute (NCI) | N/A | 2017-01-01 | This randomized pilot trial studies how well higher or lower dose cladribine, cytarabine, and mitoxantrone work in treating medically less fit patients with newly diagnosed acute myeloid leukemia or myeloid neoplasm. Drugs used in chemotherapy, such as cladribine, cytarabine, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cladribine, cytarabine, and mitoxantrone at higher or lower dose may work better in treating patients with newly diagnosed acute myeloid leukemia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Leustatin
Condition Name
Clinical Trial Locations for Leustatin
Trials by Country
Clinical Trial Progress for Leustatin
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Leustatin
Sponsor Name
